Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.

Annals of surgical oncology - 1 Oct 2020

Golan Talia, Barenboim Alex, Lahat Guy, Nachmany Ido, Goykhman Yacov, Shacham-Shmueli Einat, Halpern Naama, Brazowski Eli, Geva Ravit, Wolf Ido, Goldes Yuri, Ben-Haim Menahem, Klausner Joseph M, Lubezky Nir

Abstract excerpt

BACKGROUND: Neoadjuvant FOLFIRINOX is a standard-of-care treatment for BRPC patients. Patients with gBRCAm who have demonstrated improved response to platinum-based chemotherapy may have impaired homologous repair deficiency. This study aimed to describe the pathologic complete response rate and long-term survival for patients with germline BRCA1 or BRCA2 mutation (gBRCAm) and borderline resectable pancreatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Irinotecan

Share to Leucovorin

Share to Neoadjuvant Therapy

Share to Oxaliplatin

Share to Pancreatic Neoplasms

Source

Identifiers

PMID: 32314163
DOI: 10.1245/s10434-020-08469-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.PMID 32314163Read ↗

FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.Semantic proximity Read ↗

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancerSemantic proximity Read ↗

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOXSemantic proximity Read ↗

Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.Semantic proximity Read ↗

Results and molecular correlates from a pilot study of neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal adenocarcinomasSemantic proximity Read ↗

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean PatientsSemantic proximity Read ↗

Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.Semantic proximity Read ↗

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.Semantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers.Semantic proximity Read ↗

Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.Semantic proximity Read ↗

A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.